Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters









Database
Type of study
Language
Publication year range
1.
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group.
Fazio, F; Passucci, M; Micozzi, J; Di Landro, F; Fianchi, L; Za, T; Manieri, V M; Annibali, O; Cupelli, L; Bongarzoni, V; Gentili, S; De Padua, L; Crisanti, E; Garzia, M G; Rago, A; Piciocchi, A; Mengarelli, A; Morè, S; De Stefano, V; Bafti, M S; Martelli, M; Petrucci, M T.
Bone Marrow Transplant ; 59(6): 896-898, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38461292

Subject(s)
Antibodies, Monoclonal , Multiple Myeloma , Humans , Multiple Myeloma/therapy , Multiple Myeloma/drug therapy , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Male , Female , Middle Aged , Aged , Adult
2.
New and old monoclonal antibodies for the treatment of chronic lymphocytic leukemia.
Laurenti, L; De Padua, L; D'Arena, G; Vannata, B; Innocenti, I; Tarnani, M; Deaglio, S; Sica, S; Efremov, D G; Leone, G.
Mini Rev Med Chem ; 11(6): 508-18, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21561405

ABSTRACT

Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Antibodies, Monoclonal/immunology , Antigens, CD/chemistry , Antigens, CD/metabolism , Antigens, CD20/chemistry , Antigens, CD20/metabolism , Antigens, Neoplasm/chemistry , Antigens, Neoplasm/metabolism , Antineoplastic Agents/immunology , CD40 Antigens/antagonists & inhibitors , CD40 Antigens/metabolism , CD52 Antigen , Glycoproteins/antagonists & inhibitors , Glycoproteins/metabolism , Humans , Receptors, IgE/antagonists & inhibitors , Receptors, IgE/metabolism , Tetraspanins
3.
Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia.
Laurenti, L; Tarnani, M; Efremov, D G; Chiusolo, P; De Padua, L; Sica, S; Leone, G.
Leukemia ; 21(8): 1819-21; author reply 1821, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17443222

Subject(s)
Anemia, Hemolytic, Autoimmune/drug therapy , Antibodies, Monoclonal/administration & dosage , Antibodies, Neoplasm/administration & dosage , Antineoplastic Agents/administration & dosage , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Aged , Alemtuzumab , Anemia, Hemolytic, Autoimmune/etiology , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , Antibodies, Neoplasm/adverse effects , Antineoplastic Agents/adverse effects , Hemoglobins/analysis , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Male , Middle Aged , Treatment Outcome
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL